Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial

Emel Aygören-Pürsün, Marcin Stobiecki, Anna Valerieva, Mauro Cancian, Mark Gompels, Sofia Grigoriadou, Sorena Kiani-Alikhan, Tamar Kinaciyan, William H Yang, John Anderson, Francesco Arcoleo, Hugo Chapdelaine, Niall Conlon, Efrem Eren, Maria D Guarino, Padmalal Gurugama, Markus Magerl, Michael E Manning, Michael D Tarzi, H James Wedner, Andrea Zanichelli, Rafael Crabbé, Susan Mulders, Jonathan Levy, Li Zhu, Jochen Knolle, Anne Lesage, Peng Lu, Marc A Riedl

Open source

DOI: 10.1016/s2352-3026(26)00004-9
Published: 2026-04
Container: The Lancet Haematology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00004-9,
  title = {Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial},
  author = {Emel Aygören-Pürsün and Marcin Stobiecki and Anna Valerieva and Mauro Cancian and Mark Gompels and Sofia Grigoriadou and Sorena Kiani-Alikhan and Tamar Kinaciyan and William H Yang and John Anderson and Francesco Arcoleo and Hugo Chapdelaine and Niall Conlon and Efrem Eren and Maria D Guarino and Padmalal Gurugama and Markus Magerl and Michael E Manning and Michael D Tarzi and H James Wedner and Andrea Zanichelli and Rafael Crabbé and Susan Mulders and Jonathan Levy and Li Zhu and Jochen Knolle and Anne Lesage and Peng Lu and Marc A Riedl},
  year = {2026},
  journal = {The Lancet Haematology},
  doi = {10.1016/s2352-3026(26)00004-9},
  url = {https://doi.org/10.1016/s2352-3026(26)00004-9}
}

RIS

TY  - JOUR
TI  - Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial
AU  - Emel Aygören-Pürsün
AU  - Marcin Stobiecki
AU  - Anna Valerieva
AU  - Mauro Cancian
AU  - Mark Gompels
AU  - Sofia Grigoriadou
AU  - Sorena Kiani-Alikhan
AU  - Tamar Kinaciyan
AU  - William H Yang
AU  - John Anderson
AU  - Francesco Arcoleo
AU  - Hugo Chapdelaine
AU  - Niall Conlon
AU  - Efrem Eren
AU  - Maria D Guarino
AU  - Padmalal Gurugama
AU  - Markus Magerl
AU  - Michael E Manning
AU  - Michael D Tarzi
AU  - H James Wedner
AU  - Andrea Zanichelli
AU  - Rafael Crabbé
AU  - Susan Mulders
AU  - Jonathan Levy
AU  - Li Zhu
AU  - Jochen Knolle
AU  - Anne Lesage
AU  - Peng Lu
AU  - Marc A Riedl
PY  - 2026
JO  - The Lancet Haematology
DO  - 10.1016/s2352-3026(26)00004-9
UR  - https://doi.org/10.1016/s2352-3026(26)00004-9
ER  -

APA

Aygören-Pürsün, E., Stobiecki, M., Valerieva, A., Cancian, M., Gompels, M., Grigoriadou, S., Kiani-Alikhan, S., Kinaciyan, T., Yang, W. H., Anderson, J., Arcoleo, F., Chapdelaine, H., Conlon, N., Eren, E., Guarino, M. D., Gurugama, P., Magerl, M., Manning, M. E., Tarzi, M. D., Wedner, H. J., Zanichelli, A., Crabbé, R., Mulders, S., Levy, J., Zhu, L., Knolle, J., Lesage, A., Lu, P., & Riedl, M. A. (2026). Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(26)00004-9

Source records

crossref · retrieved 2026-09-26T03:59:16.757Z